1 active not recruiting, 1 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Nervous System Disease: new trials by email Literature Review of Nervous System Disease trials Research Report on Nervous System Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of NTLA-2001 in ATTRv-PN nexiguran ziclumeran, Normal Saline as Placebo - Neuromuscular Disease, Neuromuscular Diseases (NMD) | Phase 3 | Active not recruiting | Intellia Therapeutics | 67 | 2024-11-22 | 2026-11-05 |
| Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo - Nervous System Disease, Genetic Syndrome | Phase 3 | Completed | Quince Therapeutics S.p.A. | 176 | 2017-03-02 | 2024-05-10 |
Genetic Diseases, Inborn (2) · Nervous System Diseases (2) · Amyloid Neuropathies (1) · Amyloid Neuropathies, Familial (1) · Amyloidosis (1) · Amyloidosis, Familial (1) · Amyloidosis, Hereditary, Transthyretin-Related (1) · Heredodegenerative Disorders, Nervous System (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Peripheral Nervous System Diseases (1) · Polyneuropathies (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Nutritional and Metabolic Diseases (1) · Proteostasis Deficiencies (1)
NTLA-2001 (1) · Saline Solution (1)
Intellia Therapeutics (1) · Quince Therapeutics S.p.A. (1)
Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Mexico (1) · Norway (1) · Poland (1) · Singapore (1) · Spain (1) · Taiwan (1) · Thailand (1)
Guenter R. Janhofer, MD, PhD (1)
2015 (1)